Related Experiment Video
Updated: May 14, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Integrating immunopeptidomics with liquid biopsy for precision oncology
Doryan Masmoudi1, Catherine Alix-Panabières2, Zahra Eslami-S2
1Laboratory of Rare Circulating Human Cells - University Medical Center of Montpellier, Montpellier, France.
Molecular Aspects of Medicine
|May 12, 2026
Summary
Liquid biopsy combined with immunopeptidomics enables minimally invasive profiling of tumor antigens for personalized cancer immunotherapy. This approach overcomes limitations of traditional tissue sampling, offering dynamic patient insights.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Peptide-major histocompatibility complexes (pMHCs) are key targets in cancer immunotherapy, including T-cell receptor (TCR)-engineered T cells, peptide vaccines, and TCR-mimic antibodies.
- These therapies rely on recognizing tumor-specific antigens presented by human leukocyte antigen (HLA) molecules for targeted cancer cell elimination.
Purpose of the Study:
- To explore the integration of immunopeptidomics with liquid biopsy for minimally invasive identification of targetable tumor antigens.
- To overcome the limitations of traditional tumor tissue sampling, such as accessibility and heterogeneity, in cancer immunotherapy research.
Main Methods:
- Adaptation of immunopeptidomic methodologies to analyze circulating biomarkers like extracellular vesicles and cell-free nucleic acids.
- Profiling of HLA-bound peptides directly from blood samples obtained via liquid biopsy.
Main Results:
- Demonstrated feasibility of applying immunopeptidomics to liquid biopsy samples.
- Enabled the profiling of HLA-bound peptides in blood, reflecting tumor antigen presentation.
Conclusions:
- Integrating immunopeptidomics with liquid biopsy offers a minimally invasive strategy for precision oncology.
- This approach provides dynamic, patient-specific insights into antigen presentation, crucial for developing and monitoring personalized immunotherapies.
